Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 800 results for "Tecfidera"

Alkermes closing in on Biogen with MS rival
pharmaphorum

Biogen MS Drug Sued for Patent Infringement (BIIB)

Biogen's multiple sclerosis drug Tecfidera, which accounts for one-third of the company's revenue, is up for a Yahoo! Finance, 2 days ago
Alkermes closing in on Biogen with MS rival pharmaphorum, 2 weeks ago
[x]  

21 images for Tecfidera

Investor's Business Daily, 4 days ago
FiercePharma, 2 weeks ago
Pharma Letter, 3 weeks ago
Investor's Business Daily, 1 month ago
Zacks.com, 1 month ago
Zacks.com, 1 month ago
Nasdaq, 1 month ago
Nasdaq, 1 month ago
Pharma Letter, 2 months ago
pharmaphorum, 2 months ago
Nasdaq

Key Takeaways from Biogen's Q3 Call: Tecfidera, Pipeline, Biosimilars

Biotech company, Biogen Inc. BIIB, known for its strong position in the multiple sclerosis (MS) market, reported third quarter 2016 results before the market opened yesterday with both earnings and revenues surpassing expectations (Read more: Biogen ...
 Yahoo! Singapore1 month ago
[x]  
Investor's Business Daily

Biogen Q3 Tops; Alzheimer's Data Vs. Eli Lilly Positive

Psoriasis drug Tecfidera helped Biogen post a $50 million Q3 sales beat
 BioSpace1 month ago
[x]  
Nasdaq

Biogen (BIIB) Beats on Q3 Earnings; Tecfidera Propels Sales

Biotech company Biogen Inc.'s BIIB shares were up more than 2% in pre-market trading, with the company surpassing earnings as well as sales expectations. The company reported third-quarter 2016 earnings per share of $5.19, beating the Zacks ...
 Yahoo! Finance1 month ago Biogen (BIIB) Beats on Q3 Earnings and Sales  Yahoo! Singapore1 month ago
[x]  

Biogen's Tecfidera faces outside pressure

Dive Brief: Biogen went to court on Wednesday for the oral arguments in a patent interference trial with Forward Pharma, which is challenging the validity of Biogen's '514 patent for its multiple sclerosis drug Tecfidera. The decision of the court ...
 BioPharma Dive3 days ago

Biogen's Tecfidera was the Most Successful Drug Approved in 2013, But Other Mass. Biotechs Didn't do So Well

A new report argues that Biogen's blockbuster multiple sclerosis treatment Tecfidera was the biggest commercial success of roughly two dozen novel drugs approved in 2013, but other biotech firms in the Bay State didn't fare quite as well. In a ...
 BioSpace2 weeks ago

Biogen's Tecfidera, Amgen's Enbrel tell a tale of pricing power and weakness

Drug pricing may be a secretive affair in the U.S., but every quarter, earnings reports offer a peek behind the curtain. This time around, the numbers show pricing power dwindling away in some categories--but holding strong in others. Take this ...
 FiercePharma1 month ago
PharmaVOICE

ArticleBiogen's record 3rd-qtr boosted by strong Tecfidera performance27-10-2016

Biogen posted a record set of results late yesterday, showing that third-quarter 2016 revenues
 Pharma Letter1 month ago Biogen Reports Record Third Quarter 2016 Revenues of $3.0 Billion  Digital Journal1 month ago BIOGEN : Reports Record Third Quarter 2016 Revenues of $3.0 Billion  4 Traders1 month ago
[x]  

Biogen quarterly profit beats on MS drug Tecfidera sales

(Adds details, shares) Oct 26 (Reuters) - Biogen Inc reported a better-than-expected quarterly profit driven by sales of its multiple sclerosis drugs, sending its shares up in premarket trading. Shares of the company, which in July said Chief ...
 Sharenet1 month ago Biogen profit tops expectations; focus on CEO search, new drugs  Yahoo! Finance1 month ago UPDATE 2-Biogen profit tops expectations; focus on CEO search, new drugs  Reuters UK1 month ago
American Banking News

Biogen Inc. (BIIB) Given Market Perform Rating at BMO Capital Markets

BMO Capital Markets restated their market perform rating on shares of Biogen Inc. (NASDAQ:BIIB) in a report issued on Sunday morning. BMO Capital Markets currently has a $331.00 target price on the biotechnology company's stock, up from their prior ...
 WKRB News7 hours ago Biogen Inc. (BIIB) Rating Reiterated by BMO Capital Markets  American Banking News7 hours ago Vetr Inc. Upgrades Biogen Inc. (BIIB) to Buy  American Banking News14 hours ago Mizuho Reiterates Hold Rating for Biogen Inc. (BIIB)  Mideast Time3 days ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less